Fresenius Medical Care (NYSE:FMS) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a note issued to investors on Wednesday. The firm set a “strong-buy” rating on the stock.

Separately, Truist Financial raised their price target on shares of Fresenius Medical Care from $21.00 to $24.00 and gave the company a “hold” rating in a report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $32.25.

Fresenius Medical Care Trading Down 0.0 %

FMS stock opened at $19.17 on Wednesday. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 0.46. The company has a market cap of $11.25 billion, a price-to-earnings ratio of 21.53, a PEG ratio of 1.02 and a beta of 0.90. The business has a fifty day simple moving average of $20.80 and a 200-day simple moving average of $20.17. Fresenius Medical Care has a 52 week low of $16.37 and a 52 week high of $27.72.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.26 by $0.10. The company had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.15 billion. Fresenius Medical Care had a return on equity of 5.29% and a net margin of 2.48%. On average, equities research analysts expect that Fresenius Medical Care will post 1.5 EPS for the current year.

Institutional Trading of Fresenius Medical Care

Several large investors have recently bought and sold shares of the company. Pacer Advisors Inc. boosted its stake in shares of Fresenius Medical Care by 14,252.1% in the fourth quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock valued at $10,173,000 after purchasing an additional 484,998 shares during the period. VisionPoint Advisory Group LLC acquired a new stake in shares of Fresenius Medical Care during the fourth quarter valued at about $812,000. Partnership Wealth Management LLC acquired a new stake in shares of Fresenius Medical Care during the fourth quarter valued at about $2,340,000. Bruce G. Allen Investments LLC purchased a new stake in shares of Fresenius Medical Care during the fourth quarter worth about $31,000. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Fresenius Medical Care by 362.2% in the third quarter. Envestnet Asset Management Inc. now owns 259,033 shares of the company’s stock worth $5,580,000 after acquiring an additional 202,991 shares in the last quarter. Institutional investors and hedge funds own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.